RedHill Biopharma (RDHL), Grupo JUSTE Enter Commercialization

 

RedHill Biopharma Ltd. (NASDAQ: RDHL), together with IntelGenx Corp. (OTC: IGXT), announced that they have entered into a binding term sheet with Grupo JUSTE S.A.Q.F (“Grupo JUSTE”) granting Grupo JUSTE the exclusive license to commercialize RIZAPORT™ in Spain and a right of first refusal for additional territories. RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.

Subscribe to get the latest news